**Supplemental Table 2: Summary of clinical characteristics, complications, and laboratory values by ECMO-naïve survivors and non-survivors and all ECMO a**BMI: body mass index; bPaO2/FiO2: partial pressure of oxygen (PaO2) to fraction of inspired oxygen (FiO2); cHF: heart failure; dAST: aspartate transaminase; eALT: alanine aminotransferase; fWBC: white blood count; gCRP: C-reactive protein; fLDH: lactate dehydrogenase; iINR: international normalized ratio; jPartial thromboplastin time; kvWF: von willebrand factor; lADAMTS13: a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13, mPAI-1: plasminogen activator inhibitor-1, nTFPI: tissue factor pathway inhibitor; oMP-Tissue Factor: microparticle-bound tissue factor

|  |  |  |  |
| --- | --- | --- | --- |
|  Measure | Survivors | Non-survivors | ECMO |
| N, total patients | 35 | 11 | 9 |
| BMI,a kg/m2 (SD) | 34 (9.3) | 27 (6.0) | 34 (7.6) |
| PiO2/FiO2,b (SD) | 198 (84.6) | 142 (53.2) | 161 (64.2) |
| Ventilator Days, (SD) |    15.2 (8.7) |    15.3 (5.9) |    48.4 (18.9) |
| Major Hemorrhage, (%) | 0 (0%) | 2 (18.2%) | 7 (77.8%) |
| Major thrombotic events, (%) | 3 (8.3%) | 4 (36.4%) | 7 (77.8%) |
| Ventilator-associated pneumonia, (%) | 11 (30.5%) | 9 (81.8%) | 7 (77.8%) |
| Continuous renal replacement therapy, (%) | 3 (8.3%) | 3 (27.3%) | 4 (44.4%) |
| HFc/myocarditis, (%) | 2 (5.5%) | 0 (0%) | 1 (11.1%) |
| Arrhythmias, (%) | 3 (8.3%) | 2 (18.2%) | 1 (11.1%) |
| Death, (%) | 0 (0%) | 11 (100%) | 2 (22.2%) |
| 90 day Survival, (%) | 36 (100%) | 1 (9.1%) | 7  (81.8%) |
|  Measure | Survivors | Non-survivors | ECMO |
| AST,d U/L (SD) | 67 (132) | 64 (58) | 47 (25) |
| ALT,e U/L (SD) | 47 (62.4) | 40 (20) | 36 (19) |
| D-Dimer, ng/mL (SD) | 4896 (10242) | 6698 (12251) | 23491 (25806) |
| Hematocrit, % (SD) | 30 (6) | 27 (5) | 25 (3) |
| Platelets, x109/L (SD) | 298 (120) | 324 (153) | 162 (73) |
| WBC,f x103/mL (SD) | 10.9 (4.8) | 13.7 (8.1) | 13.9 (4.7) |
| CRP,g mg/L (SD) | 6.5 (6.8) | 14.7 (8.4) | 13.7 (13.4) |
| Fibrinogen, mg/dL (SD) | 457 (245) | 597 (209) | 431 (198) |
| Lactate, mmol/L (SD) | 2.1 (0.91) | 3.1 (1.89) | 1.1 (0.40) |
| LDH,h U/L (SD) | 506 (141) | 281 (142) | 424.1 (116) |
| pH, (SD) | 7.39 (0.07) | 7.35 (0.12) | 7.37 (0.06) |
| INR,i (SD) | 1.17 (0.13) | 1.69 (0.77) | 1.06 (0.11) |
| PTT,j seconds (SD) | 47.9 (43.7) | 49.9 (40.3) | 41.3 (11.3) |
| Creatinine, mg/dL (SD) | 1.64 (1.27) | 1.85 (1.64) | 1.67 (1.27) |
| vWF,k µg/mL (SD) | 36.9 (22.0) | 51.9 (24.5) | 39.5 (16.8) |
| ADAMTS13,l ng/mL (SD) | 517 (176) | 356 (123) | 275 (138) |
|  Measure | Survivors | Non-survivors | ECMO |
| PAI-1,m ng/mL (SD) | 26.7 (17.1) | 36.0 (18.3) | 35.9 (17.2) |
| TFPI,n ng/mL (SD) | 346 (138) | 410 (178) | 502 (156) |
| MP-Tissue Factor,o pg/mL (SD) | 1.0 (0.8) | 1.3 (1.4) | 1.1 (0.7) |
| Factor VIII activity, OD650 (SD) | 1.41 (0.23) | 1.54 (0.21) | 1.22 (0.37) |
| Anti-Xa activity, IU/mL (SD) | 0.18 (0.11) | 0.16 (0.07) | 0.13 (0.06) |
| INTEM CFT, seconds (SD) | 45 (13) | 48 (13) | 68 (31) |
| INTEM alpha angle, degrees (SD) | 81 (3) | 80 (2) | 77 (6) |
| INTEM MCF, mm (SD) | 73 (5) | 75 (5) | 67 (8) |
| INTEM LI30, % (SD) | 99 (1) | 100 (0.3) | 100 (0)  |
| EXTEM CFT, seconds  (SD) | 46 (16) | 43 (9) | 67 (33) |
| EXTEM alpha angle, degrees (SD) | 81 (3) | 82 (2) | 78 (6) |
| EXTEM MCF, mm (SD) | 75 (5) | 77 (5) | 68 (8) |
| EXTEM LI30, % (SD) | 100 (0.8) | 100 (0.4) | 100 (0.7) |
| FIBTEM MCF, mm (SD) | 31 (11) | 37 (13) | 30 (10) |